Therapeutic Drug Monitoring Market Forecasts Growth From $2.55B (2026) To $4.16B By 2032, Profiling Waters, Sekisui Diagnostics, ARUP Labs & 9 Other Key Players

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI-enabled precision dosing, mass spectrometry, remote microsampling, EHR integration, antimicrobial stewardship and emerging-market access.

Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global Therapeutic Drug Monitoring Market research report examines a sector projected to reach USD 2.55 billion in 2026 and grow at a CAGR of 8.52% to USD 4.16 billion by 2032. It provides strategic insight into clinical applications, analytical technologies, artificial intelligence, regional adoption, and emerging opportunities across the precision medicine ecosystem.

Market Overview and Growth Drivers

Therapeutic drug monitoring (TDM) enables clinicians to individualize dosing by measuring drug concentrations and interpreting results alongside patient-specific factors. It is particularly valuable for medicines with narrow therapeutic ranges, variable pharmacokinetics, or substantial toxicity risks, including immunosuppressants, antiepileptics, anti-infectives, oncology therapies, psychiatric medications, and selected biologics.

Growth is supported by aging populations, polypharmacy, organ transplantation, antimicrobial resistance, chronic disease management, and value-based care. TDM can reduce adverse drug reactions, assess medication adherence, and support evidence-based dose adjustments. These findings enable healthcare and diagnostics leaders to prioritize high-value applications and identify attractive investment or market entry opportunities.

Technology and Clinical Transformation

Liquid chromatography-mass spectrometry is improving analytical specificity and multiparameter testing, while immunoassays remain important for routine, high-throughput monitoring. Dried blood spot collection and microsampling can reduce sample requirements and extend access to remote or vulnerable patients. Automation and laboratory information systems are also improving turnaround times and workflow consistency.

TDM is increasingly evolving from an isolated laboratory result into an integrated medication optimization service. Pharmacokinetic modeling, electronic health records, pharmacogenomic context, and decision-support platforms are strengthening exposure-based dosing, particularly in transplant medicine, critical care, and antimicrobial stewardship.

Artificial Intelligence Impact

AI-enabled tools can support Bayesian dose optimization, predict concentration-time profiles, flag anomalous results, and account for kidney function, age, weight, inflammation, drug interactions, adherence, and changing physiology. When integrated with clinical and laboratory systems, these capabilities can support proactive dosing and more efficient result prioritization.

Adoption depends on validated datasets, transparent performance, interoperability, cybersecurity, regulatory compliance, and clinical governance. AI is best positioned as an assistive capability supported by pharmacist, physician, and laboratory oversight. Understanding these implementation risks supports more resilient technology selection and deployment strategies.

Regional and Economic Group Insights

North America and Europe demonstrate mature adoption through established hospital laboratories, transplant programs, stewardship frameworks, and clinical pharmacology expertise. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in tertiary care, precision medicine, and advanced diagnostics.

Latin America is progressing through improved hospital capabilities, led by Brazil and Mexico, although reimbursement and laboratory access remain uneven. Gulf countries are investing in specialty hospitals, transplant services, and digital health. African adoption is concentrated in major academic and referral centers, with opportunities in HIV, tuberculosis, infectious disease, and selected transplant programs.

G7 countries lead in Bayesian dosing, mass spectrometry, and multidisciplinary care models. ASEAN, GCC, BRICS, EU, and NATO markets present distinct opportunities shaped by infrastructure, accreditation, reimbursement, workforce capacity, and regional healthcare priorities. Comparative regional analysis helps decision-makers align expansion plans with local readiness and access constraints.

Competitive Priorities and Strategic Actions

Industry participants should focus on clinically validated solutions that improve interpretation and turnaround time, rather than measurement alone. Priority actions include:

. Standardizing sample timing, reporting formats, reference ranges, and consultation pathways.

. Expanding assays for immunosuppressants, anti-infectives, antiepileptics, psychiatric drugs, and specialty therapies.

. Integrating laboratory systems, electronic records, pharmacokinetic software, and clinical decision support.

. Establishing transparent governance and multidisciplinary oversight for AI-enabled dosing.

. Supporting clinician education, pharmacist-led services, accreditation, and outcome-based evidence.

. Using reference laboratories, microsampling, and focused test menus to expand access in emerging markets.

Key Takeaways from This Report

. The market is forecast to increase from USD 2.55 billion in 2026 to USD 4.16 billion by 2032 at an 8.52% CAGR.

. Precision dosing, antimicrobial stewardship, transplantation, and complex chronic care are central demand drivers.

. Mass spectrometry, microsampling, automation, Bayesian modeling, and AI are reshaping TDM workflows.

. Regional adoption varies significantly, creating differentiated opportunities for diagnostics, digital health, laboratories, and healthcare providers.

. Workflow integration, clinical validation, quality governance, and actionable reporting will be key competitive advantages.

Key Attributes:

Report Attribute	Details
No. of Pages	193
Forecast Period	2026 - 2032
Estimated Market Value (USD) in 2026	$2.55 Billion
Forecasted Market Value (USD) by 2032	$4.16 Billion
Compound Annual Growth Rate	8.5%
Regions Covered	Global

Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Therapeutic Drug Monitoring Market, by Product Type
7.1. Introduction
7.2. Instruments
7.2.1. Immunoassay Analyzers
7.2.2. Liquid Chromatography Systems
7.2.3. Mass Spectrometry Systems
7.3. Reagents & Kits
7.3.1. Immunoassay Kits
7.3.2. Liquid Chromatography Reagents
7.3.3. Mass Spectrometry Reagents
7.4. Software & Services
7.4.1. Consulting Services
7.4.2. Data Management Software
8. Therapeutic Drug Monitoring Market, by Technology
8.1. Introduction
8.2. Chromatography
8.2.1. Gas Chromatography
8.2.2. Liquid Chromatography
8.3. Immunoassay
8.3.1. Clia
8.3.2. Elisa
8.3.3. Fia
8.4. Mass Spectrometry
8.4.1. Single Quadrupole Mass Spectrometry
8.4.2. Tandem Mass Spectrometry
9. Therapeutic Drug Monitoring Market, by Drug Class
9.1. Introduction
9.2. Antibiotics
9.3. Anticancer Drugs
9.4. Antiepileptics
9.5. Cardiovascular Drugs
9.6. Immunosuppressants
9.6.1. Antimetabolites
9.6.2. Calcineurin Inhibitors
9.6.3. Mtor Inhibitors
10. Therapeutic Drug Monitoring Market, by Application
10.1. Introduction
10.2. Cardiology
10.3. Infectious Disease
10.3.1. Bacterial Infections
10.3.2. Fungal Infections
10.3.3. Viral Infections
10.4. Neurology
10.5. Oncology
10.5.1. Leukemia
10.5.2. Solid Tumors
10.6. Transplantation
11. Therapeutic Drug Monitoring Market, by End User
11.1. Introduction
11.2. Clinical Laboratories
11.3. Home Healthcare
11.4. Hospitals
11.5. Research Institutes
12. Therapeutic Drug Monitoring Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Therapeutic Drug Monitoring Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Therapeutic Drug Monitoring Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. ARUP Laboratories
16.3. Bio-Rad Laboratories, Inc.
16.4. Diasorin S.p.A.
16.5. F. Hoffmann-La Roche Ltd.
16.6. Laboratory Corporation of America Holdings
16.7. Quest Diagnostics Incorporated
16.8. Randox Laboratories Ltd.
16.9. Sekisui Diagnostics, LLC
16.10. Siemens Healthineers AG
16.11. Thermo Fisher Scientific Inc.
16.12. Waters Corporation
17. Key Experts

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15092026004107003653ID1111668368